Leadership / Management

Ken Horne
Chief Executive Officer
LinkedIn Page

Mr. Horne has over 15 years of experience in the life science industry as an executive, entrepreneur and investor. He joined Symic Bio as CEO in April 2014. Previously, he was a founding member of TauTona Group, an early stage life science venture capital fund. At TauTona, Mr. Horne founded Aline Aesthetics, a novel biomaterial company, where he led the company as General Manager until its acquisition by Allergan (AGN) in 2014. He also served as Vice President of Business Development for TauTona portfolio companies, which included acquisitions by LifeCell and Novadaq (NVDQ). Mr. Horne has a BS and MS degree from Stanford University in mechanical engineering and is also a Kauffman Fellow.

Nathan Bachtell Photo
Nathan Bachtell, MD
Chief Medical Officer
LinkedIn Page

Dr. Bachtell joined Symic Bio in March of 2014 and will be leading clinical research and medical affairs initiatives. Previously, he was the medical as well as global team lead in the osteoarthritis (OA) development program at Genzyme (now part of Sanofi) where he focused on symptomatic and disease modification therapies. During his time in industry Dr. Bachtell worked on biologics, cell therapies as well as medical devices, and led teams in pharmacovigilance, clinical research and medical affairs. His therapeutic focus included general orthopedics, dermatology, immune mediated diseases, and neurology. Prior to industry, he was an attending physician at a teaching hospital as well as an advisor and principal investigator for a biotechnology start up. Dr. Bachtell received his MD from UC San Francisco, completed residency at Oregon Health Sciences University and earned a Masters in Management from Harvard University.

Jocelyn Jackson Photo
Jocelyn Jackson, CPA
Chief Financial Officer
LinkedIn Page

Prior to joining Symic Bio, Ms. Jackson was the CFO of TauTona Group, an early stage life science venture. At TauTona, Ms. Jackson was responsible for the management of all finance and accounting functions, as well as investor communication. She was also closely involved in the sale of TauTona’s assets to Allergan (AGN), LifeCell and Novadaq (NVDQ). Previously, she was the Controller of CV Ingenuity, a medical device company that developed drug-coated balloon platforms, where she assisted in the sale of CV Ingenuity to Covidien (COV). Ms. Jackson started her career at Deloitte and Touche, LLP, where she spent time in both the tax and audit departments.

Glenn Prestwich
Glenn Prestwich, PhD
Chief Scientific Officer

As Presidential Professor of Medicinal Chemistry at the University of Utah, Dr. Prestwich led translational research efforts as Special Presidential Assistant for Faculty Entrepreneurism and has served as Director of the Center for Cell Signaling and of the Center for Therapeutic Biomaterials. He has authored over 650 publications and holds 38 patents. Dr. Prestwich has helped launch over nine life science companies and has advised numerous companies. He is an elected Fellow of the National Academy of Inventors and is the recipient of multiple awards, including the Utah Governor’s Medal for Science and Technology, the Rooster Prize of the International Society for Hyaluronan Science, the Volwiler Research Award, the University of Utah Distinguished Scholarly and Creative Research Award and the University of Utah Distinguished Innovation and Impact Award. Dr. Prestwich received his Ph.D. in Organic Chemistry from Stanford University.